x
The next generation of precision oncology starts with living tumor cells.
True single-cell multi-omics for a deeper view of tumor biology.
Cell Biopsy® captures live circulating tumor cells (CTCs) to enable single-cell analysis of tumor biology. Integrating DNA, RNA, protein, and matched ctDNA, it provides a multidimensional view of tumor characteristics.
Tumors are not uniform. They are dynamic ecosystems made up of diverse cellular populations with distinct genetic, transcriptomic, and proteomic profiles.
Population-level measurements can average away critical differences, potentially obscuring rare cell populations, evolving clones, resistance-associated biology,
and therapeutic target expression.
The way we study cancer is evolving. From tissue biopsy to liquid biopsy to Cell Biopsy®, each approach provides a different window into tumor biology—with cellular resolution offering a deeper view of tumor heterogeneity and evolution.
A static view of tumor biology.
A minimally invasive view of tumor biology through circulating tumor DNA.
A cellular view of tumor biology.
Measure DNA, RNA, and protein at the level of individual tumor cells—
preserving biological differences that population-level analysis can miss.
Genomic alterations and genomic instability.
Transcriptomic activity and molecular programs.
Protein expression and biomarker profiles.
True single-cell multi-omics characterizes multiple molecular layers at the level of individual tumor cells, preserving biological heterogeneity that population-level analysis can obscure.
Investigate the cellular populations underlying tumor heterogeneity,
clonal evolution, therapeutic resistance and target expression.
OncoIncytes® is our proprietary technology platform designed to capture live circulating tumor cells and integrate DNA, RNA, protein, and matched ctDNA—enabling a deeper, single-cell view of tumor biology.
Research teams often spend months organizing and harmonizing siloed omics, imaging, and clinical data before analysis can begin. iCore brings these data sources together, automates quality control and harmonization, and enables plain-language queries across studies—helping teams move from data to scientific insight faster.
Move from study design to assay execution without building a bioinformatics workflow from scratch.
Evaluate pilot cohorts early and make informed decisions without waiting for a full study.
Automated QC, harmonization, and cross-study querying begin as data arrives.
Built with 21 CFR Part 11, HIPAA, & GDPR compliance in mind from day one.
Characterize biomarkers, therapeutic targets, and mechanisms of resistance to inform drug development.
Investigate tumor biology at single-cell resolution and connect molecular insights to translational research.
Measure target expression directly on live circulating tumor cells using fresh blood samples from cancer patients.
Explore tumor heterogeneity, target expression, and emerging resistance to uncover potential biomarkers.
TKI therapy is a standard treatment approach for EGFR-mutant NSCLC, yet resistance can emerge through bypass-pathway alterations that may be undetectable in bulk ctDNA.
OncoIncytes® detects bypass-pathway mutations in single circulating tumor cells at baseline, capturing private and subclonal variants that may be diluted or missed in bulk ctDNA analysis.
In a pilot cohort of 60 patients, 15 carried a single-cell TKI resistance signature. Patients with the signature experienced earlier progression and shorter overall survival, supporting the potential of single-cell resistance profiling for earlier patient stratification.
Hazard ratio for death
95% CI 2.7–7.5
P-value
Log-rank test
Median PFS with
resistance signature
Resistance rate
15 of 60 patients
Pilot study, homogeneous EGFR-mutant NSCLC cohort (n = 60). OncoIncytes® CTC + ctDNA.
Our work spans circulating tumor biology, single-cell analysis, multi-omics, and AI-enabled analytics—from technology development and validation to translational research. Our platform has been evaluated with clinicians and academic partners across the US, Europe, and India.
Samples Processed
Patient samples processed through the platform across studies in the US, Europe, and India.
CTC Positivity Rate
CTCs detected across diagnosed patients with stage II–IV disease, spanning eight cancer types.
Metastatic Capture Rate
Circulating tumor cells recovered from nearly every metastatic sample analyzed.
Targets from a Single Cell
Quantitative protein expression measured across ADC and TCE targets using oligo-tagged antibodies.
1Cell.AI is building the technology foundation for a more precise view of cancer—moving beyond population-level molecular averages toward live, cell-resolved tumor biology.
Clinical Studies
Across 3 continents
ASCO · AACR · ESMO · ISLB
Scientific presentations across leading oncology and pathology conferences.
Peer-Reviewed Articles
Published research, with 9 additional manuscripts in preparation.
Patent Families
Granted and filed patent families supporting our technology platform.
Trademarks
Trademarks filed across our technology and product portfolio.
55 ASCO · 33 AACR · 4 ESMO · 10 ISLB, across the world’s leading oncology congresses,
with a studies and KOL network spanning leading cancer centers.
Discover how 1Cell.Ai is bringing true single-cell multi-omics to oncology research, drug development and translational medicine.